WESCAP Management Group Inc. Has $352,000 Stock Position in Pfizer Inc. (NYSE:PFE)

WESCAP Management Group Inc. increased its holdings in Pfizer Inc. (NYSE:PFE) by 29.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,275 shares of the biopharmaceutical company’s stock after purchasing an additional 3,000 shares during the period. WESCAP Management Group Inc.’s holdings in Pfizer were worth $352,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. Private Portfolio Partners LLC boosted its holdings in shares of Pfizer by 57.8% during the 4th quarter. Private Portfolio Partners LLC now owns 48,873 shares of the biopharmaceutical company’s stock worth $1,297,000 after buying an additional 17,907 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in Pfizer by 7.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock valued at $2,029,604,000 after acquiring an additional 5,350,381 shares during the period. RFG Bristol Wealth Advisors LLC bought a new position in shares of Pfizer in the fourth quarter worth about $552,000. First Wilshire Securities Management Inc. acquired a new position in shares of Pfizer during the 4th quarter worth about $244,000. Finally, Knott David M Jr boosted its stake in Pfizer by 13.4% during the 4th quarter. Knott David M Jr now owns 254,537 shares of the biopharmaceutical company’s stock valued at $6,753,000 after purchasing an additional 30,000 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Down 3.2 %

Shares of NYSE PFE opened at $24.53 on Wednesday. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The company has a 50-day moving average of $26.00 and a two-hundred day moving average of $26.84. The company has a market cap of $139.09 billion, a PE ratio of 17.39, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.10 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

PFE has been the topic of several recent analyst reports. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup dropped their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Truist Financial dropped their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.